Document:

Exhibit 10.4

 

WAIVER AND FIRST AMENDMENT
AGREEMENT

 

This FIRST AMENDMENT
AGREEMENT (this “Agreement”) is made and entered into as of January 5, 2018 (“Amendment Date”)
by and between Inpixon, a Nevada corporation (the “Company”), and the signatory hereto (the “Holder”)
holding that certain outstanding Convertible Promissory Note, issued on November 17, 2017 (the “Note”) issued
pursuant to that Securities Purchase Agreement, dated November 17, 2017 (the “SPA”) by and between the Company
and the Holder. This Agreement amends the Note and the SPA and the SPA (as defined below) in accordance with Section 9.12 of the
SPA and Section 18 of the Note. In this Agreement, the Company and the Holder are sometimes referred to singularly as a “party”
and collectively as the “parties”. Capitalized terms not otherwise defined herein shall have the meanings set forth
in the Note or the SPA (as applicable).

 

WHEREAS, as
of the Amendment Date, the Holder holds the Note in an aggregate principal amount of $1,745,000; and

 

WHEREAS, subject
to the terms and conditions herein, the Company and the Holder desire to amend the SPA and the Note in accordance with this Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants of the parties as hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

 

AGREEMENT

 

1.
Waiver. The Holder hereby waives (a) any requirement in the SPA and the Note, including, but not limited to, the
requirements in Section 7 of the SPA to maintain the Share Reserve until the date on which the Company files an amendment to its
Articles of Incorporation for the purpose of increasing its authorized shares of Common Stock and in no event later than February
15, 2018 (the “Reserve Deadline”); provided, however, that the Company covenants that as of the Reserve Deadline
it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose
of issuance upon conversion of the Note and payment of interest under the Note, not less than 150% of the aggregate number of shares
of Common Stock as shall be issuable upon the conversion of the then outstanding principal amount of the Note and payment of interest
thereunder (b) any right of conversion under the Notes until the six month anniversary of the Effective Date.

 

2.
Agreement. The Holder hereby agrees that any adjustments to the Conversion Price pursuant to Section 8 of the SPA
and Section 7.1 of the Note shall be subject to the limitations and terms described in Proposal 8 of the Definitive Schedule 14A
filed by the Company on November 8, 2017 and approved by the Company’s stockholders in accordance with Nasdaq Listing Rule
5635(d) on December 8, 2017 and a subsequent amendment to the SPA and the Notes which shall be approved by the Nasdaq staff and
include a $0.29 floor (subject to adjustment in accordance with the Note).

 

3.
Conversion Price. Section 3.2 of the Note is hereby amended and restated as follows:
Subject to adjustment as set forth in this Note, the price at which Lender has the right to convert all or any portion of the
Outstanding Balance into Common Stock is $0.45 per share of Common Stock (the “Conversion Price”); provided,
however, that, the Conversion Price may be reduced to a price that is equal to 70% of the closing bid price reported
by the Nasdaq Stock Market as of the date immediately prior to each applicable conversion date subject
to and only upon approval by the Company’s stockholders in accordance with Nasdaq Listing Rule 5635(d) (“Alternate
Conversion Price Approval”). Notwithstanding the foregoing, in no event shall the Conversion Price be equal to
a price that is less than $0.10 (the “Alternate Conversion Price”).

 

4.
Event of Default. Section 4.1(l) of the Note is hereby amended and restated as follows: “Borrower fails
to establish the Share Reserve by the Reserve Deadline or otherwise maintain the Share Reserve as required under the Purchase Agreement.”

 

     

     

    

 

5.
Effect on Transaction Documents.

 

a)
As of the date hereof, each reference in the SPA to “this Agreement,” “hereunder,” “hereof”
or words of like import referring to the SPA, and each reference in the Note to “the Purchase Agreement,” “thereunder,”
“thereof” or words of like import referring to the SPA shall mean and be a reference to the SPA, as amended by this
Agreement.

 

b)
As of the date hereof, each reference in the Note to “this Note,” “hereunder,” “hereof”
or word of like import referring to the Note, and each reference in the SPA or the other Transaction Documents to the “Note,”
“thereunder,” “thereof” or words of like import referring to the Note shall mean and be a reference to
the Notes, as amended by this Agreement.

 

c)
Except as expressly set forth herein, the terms and conditions of the Transaction Documents shall remain in full force and
effect and each of the parties reserves all rights with respect to any other matters and remedies.

 

6.
Fees and Expenses. Each party shall pay the fees and expenses of its advisors, counsel, accountants and other experts,
if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance
of this Agreement.

 

7.
Miscellaneous.

 

a)
This Agreement and the other Transaction Documents contain the entire agreement of the Holders and the Company with respect
to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. This Agreement
may not be amended, modified or supplemented, and no provision of this Agreement may be waived, other than by a written instrument
duly executed and delivered by a duly authorized officer of the Company and the Holders of majority of the then outstanding Notes.

 

b)
It is hereby understood that this Agreement does not constitute an admission of liability by any party, including any admission
of default under the Transaction Documents.

 

c)
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such action
or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party hereto shall commence an action or proceeding to enforce any provisions of this
Agreement, then, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action
or proceeding.

 

d)
This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original
and, all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile
transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature
is executed) the same with the same force and effect as if such facsimile signature were the original thereof.

 

e)
The Company shall file a Current Report on Form 8-K with the Commission on or before the fourth business day following the
Amendment Date describing the terms of the transactions contemplated hereby.

 

[SIGNATURE PAGE FOLLOWS]

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed on the day and year first above written.

 

	 	INPIXON
	 	 	 
	 	By: 	/s/ Nadir Ali
	 	 	Name:  Nadir Ali
	 	 	Title:    Chief Executive Officer

 

[SIGNATURE PAGE OF HOLDER FOLLOWS]

 

    	 	3	 

     

    

 

	CHICAGO VENTURE PARTNERS, L.P.	 
	 	 	 
	By: 	/s/ John M. Fife	 
	Name: John M. Fife	 
	Authorized Signatory	 

 

[HOLDERS
SIGNATURE PAGE TO INPIXON NOVEMBER NOTE FIRST AMENDMENT AGREEMENT]

 

    	 	4Exhibit 10.5

 

LEAK-OUT AGREEMENT

 

January __, 2018

 

This agreement (the
“Leak-Out Agreement”) is being delivered to you in connection with an understanding by and among Inpixon, a
Nevada corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively,
the “Holder”).

 

Reference is hereby
made to (a) the Securities Purchase Agreement, dated January ___, 2018, by and among the Company and the certain purchasers signatory
thereto (the “SPA”), pursuant to which the Holder acquired (i) shares of Common Stock (“Shares”)
and (ii) Warrants to purchase Common Stock (collectively, the “Holder Warrants” and together with the Shares,
the “Securities”), and (b) the registration statement on Form S-3 (File No. 333-204159) (“Registration
Statement”). Capitalized terms not defined herein shall have the meaning as set forth in the SPA.

 

On January 9, 2018
(such date, the “Effective Date” and such date and only such date, the “Restricted Period”),
neither the Holder, nor any Affiliate of such Holder which (x) had or has knowledge of the transactions contemplated by the SPA,
(y) has or shares discretion relating to such Holder’s investments or trading or information concerning such Holder’s
investments, including in respect of the Securities, or (z) is subject to such Holder’s review or input concerning such Affiliate’s
investments or trading (together, the “Holder’s Trading Affiliates”), collectively, shall sell dispose
or otherwise transfer, directly or indirectly, (including, without limitation, any sales, short sales, swaps or any derivative
transactions that would be equivalent to any sales or short positions) on any Trading Day during the Restricted Period (any such
date, a “Date of Determination”), Shares or shares of the Company’s Common Stock otherwise acquired following
the Effective Date, in an amount more than ___%1 of the trading volume of Common Stock as reported by Bloomberg, LP
for the applicable Date of Determination.

 

Notwithstanding anything
herein to the contrary, during the Restricted Period, the Holder may, directly or indirectly, sell or transfer all, or any part,
of the Shares (the “Restricted Securities”) to any Person (an “Assignee”) in a transaction
which does not need to be reported on the Nasdaq consolidated tape, without complying with (or otherwise limited by) the restrictions
set forth in this Leak-Out Agreement; provided, that as a condition to any such sale or transfer an authorized signatory of the
Company and such Assignee duly execute and deliver a leak-out agreement in the form of this Leak-Out Agreement (an “Assignee
Agreement”, and each such transfer a “Permitted Transfer”) and, subsequent to a Permitted Transfer,
sales of the Holder and the Holder’s Trading Affiliates and all Assignees (other than any such sales that constitute Permitted
Transfers) shall be aggregated for all purposes of this Leak-Out Agreement and all Assignee Agreements.

 

Any notices, consents,
waivers or other communications required or permitted to be given under the terms of this Leak-Out Agreement must be in writing
and shall be given in accordance with the terms of the SPA.

 

This Leak-Out Agreement
constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes all prior negotiations,
letters and understandings relating to the subject matter hereof and are fully binding on the parties hereto.

 

 

1
Pro rata portion of 35% among investors executing Leak-Out Agreements, based on Subscription Amount.

 

     

     

    

 

This Leak-Out Agreement
may be executed simultaneously in any number of counterparts. Each counterpart shall be deemed to be an original, and all such
counterparts shall constitute one and the same instrument. This Leak-Out Agreement may be executed and accepted by facsimile or
PDF signature and any such signature shall be of the same force and effect as an original signature.

 

The terms of this Leak-Out
Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective successors and
assigns.

 

This Leak-Out Agreement
may not be amended or modified except in writing signed by each of the parties hereto.

 

All questions concerning
the construction, validity, enforcement and interpretation of this Leak-Out Agreement shall be governed by Sections 5.9 and 5.20
of the SPA.

 

Each party hereto acknowledges
that, in view of the uniqueness of the transactions contemplated by this Leak-Out Agreement, the other party or parties hereto
will not have an adequate remedy at law for money damages in the event that this Leak-Out Agreement has not been performed in accordance
with its terms, and therefore agrees that such other party or parties shall be entitled to seek specific enforcement of the terms
hereof in addition to any other remedy it may seek, at law or in equity.

 

The obligations of
the Holder under this Leak-Out Agreement are several and not joint with the obligations of any other holder of any of the Securities
issued under the SPA (each, an “Other Holder”), and the Holder shall not be responsible in any way for the performance
of the obligations of any Other Holder under any such other agreement. Nothing contained in this Leak-Out Agreement, and no action
taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and Other Holders as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting
in concert or as a group with respect to such obligations or the transactions contemplated by this Leak-Out Agreement and the Company
acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or
the transactions contemplated by this Leak-Out Agreement or any other agreement. The Company and the Holder confirm that the Holder
has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and
advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights
arising out of this Leak-Out Agreement, and it shall not be necessary for any Other Holder to be joined as an additional party
in any proceeding for such purpose.

 

The Company hereby
represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered
to any Other Holder with respect to any restrictions on the sale of Securities substantially in the form of this Leak-Out Agreement
(or any amendment, modification, waiver or release thereof) (each a “Settlement Document”), is or will be more
favorable to such Other Holder than those of the Holder and this Agreement. If, and whenever on or after the date hereof, the Company
enters into a Settlement Document, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence
thereof and (ii) the terms and conditions of this Leak-Out Agreement shall be, without any further action by the Holder or the
Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive
the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Settlement Document, provided
that upon written notice to the Company at any time the Holder may elect not to accept the benefit of any such amended or modified
term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect
immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holder.
The provisions of this paragraph shall apply similarly and equally to each Settlement Document.

 

[The remainder of the page is intentionally
left blank]

 

    	 	2	 

     

    

 

[Signature Page to INPX Leak-out]

 

	 	Sincerely,
	 	 
	 	inpixon
	 	 	 
	 	By: 	 
	 	 	Name:
	 	 	Title:

 

Agreed to and Acknowledged:

 

	“HOLDER”	 
	 	 
	 	 
	 	 	 
	By: 	 	 
	 	Name: 	 
	 	Title:	 

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]